Thaddeus Pullano
Corporate Officer/Principal en Acambis Plc .
Perfil
Thaddeus Pullano joined Acambis Plc in 2003 and currently serves Vice President of Quality Systems.
He worked at Burroughs Wellcome and Wyeth Vaccines.
Dr. Pullano has 20 years of experience in biomedical and biopharmaceutical research & development, product development, quality control and quality assurance management.
He holds a PhD degree.
Cargos activos de Thaddeus Pullano
Empresas | Cargo | Inicio |
---|---|---|
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Thaddeus Pullano.
Empresas | Cargo | Fin |
---|---|---|
BioVex Ltd.
BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
Burroughs Wellcome | Corporate Officer/Principal | - |
Formación de Thaddeus Pullano.
The State University of New York | Undergraduate Degree |
University of Southern California | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 3 |
---|---|
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Health Technology |
Burroughs Wellcome | |
BioVex Ltd.
BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
- Bolsa de valores
- Insiders
- Thaddeus Pullano